NewAmsterdam Pharma Co NV (NAMS) PT Raised to $44 at RBC Capital Nov 5, 2025 03:59PM
RBC Capital Reiterates Outperform Rating on NewAmsterdam Pharma Co NV (NAMS) Jun 3, 2025 05:52AM
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA Jan 13, 2025 12:50PM
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results May 9, 2024 08:00AM
NewAmsterdam Pharma (NAMS) Prices 4.49M Share Offering at $19/sh Feb 14, 2024 05:47AM


Feb 13, 2024 10:40PM NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Feb 13, 2024 04:01PM NewAmsterdam Pharma (NAMS) Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
Feb 13, 2024 04:01PM NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
Oct 30, 2023 05:11AM RBC Capital Starts NewAmsterdam Pharma Co NV (NAMS) at Outperform, 'See Potential For Obicetrapib To Be a Best-In-Class CETP Inhibitor'